Vitiligo Drugs Market 2018-2026 Report On Universal Market, Upright And Forecast, By Companies And Applications
Vitiligo is a skin
condition characterized by white patches on the skin. It is also
known as skin depigmentation. In skin depigmentation, the skin's
pigment-making cells known as melanocytes are lost or destroyed,
which result into patches. The patches of affected skin appear white
and usually have sharp margins. In most of the cases, the patches
emerge on the skin, which is more exposed to sunlight. Although the
disease can occur at any age, it is more observed in the
mid-twenties. Although the disease does not affect the physical
health of a person, it creates concerns about physical appearance and
ethical identity of the person. The exact cause of Vitiligo is not
known. It is mostly observed in people with family history of
autoimmune disease. Vitiligo is classified into two types: segmental
and non-segmental. In segmental vitiligo, only one side of body is
affected by skin depigmentation. In non-segmental vitiligo, both
sides of body are affected by skin depigmentation and the affected
area of the skin expands with time. In general, non-segmental
vitiligo is more common than segmental vitiligo.
Request For a
Sample Copy Of This Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/2447
Vitiligo
Drugs Market Drivers
Vitiligo drugs
market is expected to witness significant growth, owing to
development of new therapies for vitiligo. For instance, in Feb 2018,
researchers at Yale University School of Medicine discovered a new
therapy for the treatment of vitiligo. The therapy can aid in
returning the color of depigmented skin due to vitiligo. The new
combination therapy includes oral medication of Xeljanz
(tofacitinib) and ultraviolet-B light therapy. Xeljanz is used in the
treatment of rheumatoid arthritis and ultraviolet B (UVB) light
therapy is an effective treatment for psoriasis. UVB penetrates the
skin and slows the growth of affected skin cells.
Moreover, increasing
pipeline studies to develop new drugs for the treatment of vitiligo
is expected to drive vitiligo drugs market growth. For instance, in
December 2016, Nicolaus Copernicus University initiated the phase 1
and phase 2 clinical trial for Atorvastatin calcium salt and
Simvastatin-acid sodium salt. The study has been initiated for the
evaluation of vitiligous lesions repigmentation after the
administration of Atorvastatin calcium salt and Simvastatin-acid
sodium salt in patients with active vitiligo. The study is estimated
to complete by April 2019.
However, adoption of
unlicensed medication may restraint the vitiligo drugs market growth.
Topical Calcineurin inhibitors (Tacrolimus and Pimecrolimus) used for
treating vitiligo are unlicensed medicines. Prescription of
unlicensed medicines for the treatment of vitiligo is attributed to
the assumption that these medicine are more effective and offer some
benefits in the treatment and show lesser side effect unlike
corticosteroids that cause thinning of the skin.
Vitiligo
Drugs Market - Taxonomy
By Drugs
Class
-
Calcineurin Inhibitors
-
Corticosteroids
-
Immunomodulator
-
Psoralens
By Route of
Administration
-
Oral
-
Topical
Vitiligo
Drugs Market- Regional Analysis
On the basis of
region, the global vitiligo drugs market is segmented into North
America, Latin America, Europe, Asia Pacific, Middle East, and
Africa.
Increasing
prevalence of vitiligo in North America is expected to boost the
vitiligo drug market growth during the forecast period. For instance,
according to American Academy of Dermatology, in November 2013, over
150,000 people in the U.S. across all age were treated for vitiligo.
The overall cost incurred was over US$ 328 per patient and total
medical cost was valued at US$ 49 million.
Asia Pacific is
expected to witness significant growth in the vitiligo drugs market,
owing to presence of major players in this region and launch of new
products. For instance, in 2014, Dr. Reddy’s Laboratories, an
India-based multinational pharmaceutical company, launched
Melgain lotion to treat vitiligo in partnership with Issar
Pharmaceuticals Pvt Ltd. Under the partnership, Issar Pharmaceuticals
was tasked to manufacture the product and Dr. Reddy’s Laboratories
for its commercialization.
Key players
operating in the global vitiligo drugs market include, AXIM
Biotechnologies, Dr. Reddy’s Laboratories, Boston Pharmaceutical,
Castle Creek Pharma, Dermavant Sciences, JN Biosciences,
Bristol-Myers Squibb, Incyte Corporation, Clinuvel Pharmaceuticals,
Glenmark Pharmaceuticals, and Galderma laboratories (Nestlé Skin
Health).
Click To Read
More On Vitiligo
Drugs Market
Comments
Post a Comment